Thanks to your generous donations during our Year-End Fundraising Drive, Phase II of the PFS culprit-genes study at the University of Milano (UniMi) has been fully funded.
Roberto Cosimo Melcangi, PhD, Head of the Neuroendocrinology Unit in the Department of Pharmacological and Biomolecular Sciences at UniMi, last summer wrapped up the research phase of this study, which has identified several genes that are likely responsible for the side effects observed in PFS patients.
He needed additional funding, however, to analyze his data and write a formal study based on that analysis. So we made it our mission to raise the target amount by the end of January.
Having achieved that goal on schedule, we’d like to extend special thanks to those first-time donors who dug deep in their pockets to help ensure that Prof. Melcangi and his team are able to continue their ongoing investigations into PFS.
“We’re now set to work full-steam-ahead on completing this critical genetic research,” Prof. Melcangi tells us. “And while there are never any fixed time lines in science, we’ll try our best to complete the study by the end of spring, and submit it for peer review well before the end of the year.”